


PHARMACEUTICAL 2019

Mylan II B.V. Rank 72 of 371







RealRate

PHARMACEUTICAL 2019

Mylan II B.V. Rank 72 of 371

The relative strengths and weaknesses of Mylan II B.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mylan II B.V. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 232% points. The greatest weakness of Mylan II B.V. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 47%, being 379% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	6,367,700
Cost of Goods Sold	7,432,300
Intangible Assets	23,412,400
Liabilities, Current	4,587,800
Liabilities, Non-Current	14,258,000
Other Assets	784,600
Other Compr. Net Income	-1,072,600
Other Expenses	438,700
Other Liabilities	1,722,000
Other Net Income	-64,900
Property and Equipment	2,170,200
Research and Development	704,500
Revenues	11,433,900
Selling, General and Administrative Expense	2,441,000

Output Variable	Value in 1000 USD
Assets	32,734,900
Liabilities	20,567,800
Expenses	11,016,500
Stockholders Equity	12,167,100
Net Income	352,500
Comprehensive Net Income	-183,800
Economic Capital Ratio	47%

